Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Drug survival reflects a drug’s effectiveness, safety, and tolerability. We assessed the drug survival of biologics used to treat psoriasis in a prospective national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register (BADBIR)). The survival rates of the f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of investigative dermatology 2015-11, Vol.135 (11), p.2632-2640
Hauptverfasser:	Warren, Richard B., Smith, Catherine H., Yiu, Zenas Z.N., Ashcroft, Darren M., Barker, Jonathan N.W.N., Burden, A. David, Lunt, Mark, McElhone, Kathleen, Ormerod, Anthony D., Owen, Caroline M., Reynolds, Nick J., Griffiths, Christopher E.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - administration & dosage Adult Biological Products - administration & dosage Biological Products - pharmacokinetics Biological Therapy - methods Cohort Studies Dermatology Dose-Response Relationship, Drug Drug Administration Schedule Etanercept - administration & dosage Etanercept - pharmacokinetics Female Humans Infliximab - administration & dosage Infliximab - pharmacokinetics Kaplan-Meier Estimate Male Maximum Tolerated Dose Middle Aged Proportional Hazards Models Prospective Studies Psoriasis - diagnosis Psoriasis - drug therapy Registries Societies, Medical Ustekinumab - administration & dosage Ustekinumab - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!